Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07030959 · ClinicalTrials.gov registry record · Phase 1
Study of AUBE00 in Patients With Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Chugai Pharmaceutical.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 4
- Study locations
NCT07030959: Recruiting Phase 1 study of Solid Tumors, sponsored by Chugai Pharmaceutical.
NCT07030959 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Chugai Pharmaceutical. The registered enrollment target is 130 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (54% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07030959, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Chugai Pharmaceutical.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total number of patients in this study will be approximately 90 to 130.
Primary Outcome
Incidence, nature, and severity of adverse events (AEs), with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG AUBE00
Study Locations (4)
Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Chiba
- National Cancer Center Hospital East - Kashiwa
Tokyo
- National Cancer Center Hospital - Chuo-ku
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
What NCT07030959 shows while recruiting
NCT07030959 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT07030959 reports a single indexed study location in Michigan, Texas, Chiba.
Frequently Asked Questions
What is clinical trial NCT07030959 about?
NCT07030959 is a clinical study titled "Study of AUBE00 in Patients With Solid Tumors". This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total numbe...
What is the current status of trial NCT07030959?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2025-06-05. Estimated completion is 2029-12-31.
What conditions does trial NCT07030959 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT07030959?
The interventions under investigation include: Cetuximab (DRUG), AUBE00 (DRUG).
Who is sponsoring clinical trial NCT07030959?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07030959 being conducted?
This trial has 4 study locations across Michigan, Texas, Chiba, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07030959's enrollment target sits among peer trials
130 45th of 125 higher than 81 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI